A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly · Obesity · Overweight
Phase 3
Active, not recruiting
586
2026-07
Evidence dashboardStudies since 2019Updated Jul 31, 2026
RetatrutideClinical Trials.
A source-linked view of every Retatrutide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 34
- Recruiting
- 2
- Completed
- 22
- Terminated
- 0
- Results posted
- 2
- Average enrollment
- 825
- Countries
- 38
- Highest phase
- Phase 3
Largest indexed study
10,000 participants · NCT06383390 →Developer / research origin
Eli Lilly
Evidence summary
Activity is not efficacy.
Retatrutide appears in 34 indexed studies: 2 recruiting, 22 completed and 2 with registry results posted. The highest registered development stage in this snapshot is Phase 3. These counts measure registry activity; they do not establish that Retatrutide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly · Type 2 Diabetes
Phase 3
Active, not recruiting
320
2026-07
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly · Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)
Phase 3
Active, not recruiting
10,000
2026-07
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Eli Lilly · Obesity
Phase 3
Active, not recruiting
800
2026-07
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly · Metabolic Dysfunction-Associated Steatotic Liver Disease
Phase 3
Recruiting
4,500
2026-07
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Eli Lilly · Diabetes Mellitus · Insulin Sensitivity
Phase 1
Active, not recruiting
95
2026-07
Showing 6 of 11 studies
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly · Obesity · Cardiovascular Diseases
Phase 3
Completed
1,946
2026-07
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly · Type 2 Diabetes · Obesity
Phase 3
Completed
1,152
2026-07
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
Eli Lilly · Type 2 Diabetes Mellitus
Phase 1
Completed
80
2026-06
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 3
Completed
2,335
2026-06
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
Eli Lilly · Diabetes Type 2
Phase 3
Completed
537
2026-03
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
Eli Lilly · Obesity · Overweight
Phase 3
Completed
445
2026-01
Showing 6 of 22 studies
No studies in this snapshot.
Full study index
Search Retatrutide trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
34 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 41160422 ↗Heerspink HJL, van Raalte DH, Bjornstad P, Bunck MC, Wu P, Tunali I, Milicevic Z, Koeneman L. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrol Dial Transplant. 2026 May 29;41(6):1058-1068. doi: 10.1093/ndt/gfaf230.Linked from NCT06383390PMID 42250575 ↗Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B, Liu R, Chen Y, Patel H, Bartee A. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026 Jun 13;407(10546):2402-2413. doi: 10.1016/S0140-6736(26)00967-0. Epub 2026 Jun 6.Linked from NCT06354660PMID 41201783 ↗Kanu C, Clucas C, Skalicky A, Samuelson A, Goetz I, Neff LM, Boye KS, Karn H. Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity. Adv Ther. 2026 Jan;43(1):150-164. doi: 10.1007/s12325-025-03386-2. Epub 2025 Nov 7.Linked from NCT04881760PMID 38858523 ↗Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024 Jul;30(7):2037-2048. doi: 10.1038/s41591-024-03018-2. Epub 2024 Jun 10.Linked from NCT04881760PMID 37366315 ↗Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26.Linked from NCT04881760PMID 40609566 ↗Coskun T, Wu Q, Schloot NC, Haupt A, Milicevic Z, Khouli C, Harris C. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025 Aug;13(8):674-684. doi: 10.1016/S2213-8587(25)00092-0. Epub 2025 Jun 30.Linked from NCT04867785PMID 37385280 ↗Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26.Linked from NCT04867785PMID 36354040 ↗Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022 Nov 26;400(10366):1869-1881. doi: 10.1016/S0140-6736(22)02033-5. Epub 2022 Oct 27.Linked from NCT04143802
Related pages
Keep researching Retatrutide.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.
DatabaseRetatrutide database page →Research guideRead the Retatrutide guide →Market comparisonRetatrutide research listings →Lab reportsSearch the COA ledger →Research vendor recordAscension Peptides →Research vendor recordNura Peptide →Research vendor recordEZ Peptides →Research vendor recordNOVA Labs →Source registrySearch ClinicalTrials.gov ↗